Satellos Bioscience Inc. announced the appointment of Dr. Rima Al-awar, PhD and Mr. Adam Mostafa to its board of directors on December 5, 2021. An accomplished pharmaceutical executive with expertise spanning target discovery to lead identification and clinical candidate nomination, Dr. Al-awar presently serves as Head - Therapeutic Innovation and Drug Discovery at the Ontario Institute for Cancer Research, a unit she founded in 2008 to seek out and translate the most promising ideas from Ontario's academic community into new therapeutic treatments for the benefit of cancer patients. Under Dr. Al-awar's leadership, the team of more than 30 multi-disciplinary researchers advanced lead drug candidates against difficult to drug cancer targets (BCL6 and WDR5) which were the basis of substantial pharmaceutical development partnerships entered into through the OICR's investment and commercialization arm, FACIT. A seasoned and accomplished financial leader, Mr. Mostafa is the Chief Financial Officer of X4 Pharmaceuticals and has previously held senior roles in both the biotech/life sciences and investment banking sectors. At X4 he works closely with the CEO and Board of Directors on all strategic and financial matters, including the close of its 2019 reverse merger with Arsanis and subsequent public listing on NASDAQ and follow-on financings. As Chief Financial Officer, Mr. Mostafa oversees teams including finance, business development, commercial and corporate communications, leading all investor and public relations initiatives and building strong ties with the investor and investment banking communities. Coinciding with the appointments of Dr. Al-awar and Mr. Mostafa, the Company also wishes to announce the resignations of Dr. John Holyoake, PhD and Dr. Michael Rudnicki, PhD as directors of the Company. Dr. Rudnicki will remain as an officer of Satellos, continuing in his role as Chief Scientific Officer. Mr. Mostafa will act as Chair of the Audit Committee, which was previously chaired by Dr. Holyoake.